Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 18, 2024

FDA committee recommends BMS-2seventy’s Abecma

The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted in favour of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) for treating triple-class exposed relapsed or refractory multiple myeloma.

BMS and 2seventy bio have submitted supplemental biologics license application seeking approval for Abecma. Credit: Bristol-Myers Squibb Company.